Rocket Pharmaceuticals, Inc.(RCKT) stock price and fundamentals

Biotechnology · Cranbury, NJ

$2.48-0.13 (-5.17%)

Delayed quote: Oct 6, 2026, 1:55 PM EDT

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia. Complementing these, Rocket Pharmaceuticals also has an in vivo adeno-associated virus program underway for Danon disease, a serious multi-organ lysosomal storage disorder that tragically often results in early mortality due to heart failure. To facilitate its extensive research and development efforts, the company has established key licensing partnerships with esteemed institutions such as the Fred Hutchinson Cancer Research Center, European research bodies including CIEMAT and its collaborators (Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz), UCL Business PLC (in conjunction with CIEMAT), The Regents of the University of California, and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. maintains its primary corporate location in Cranbury, New Jersey.

Cranbury, NJ

202 employees

rocketpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Gaurav D. Shah

View full financials

Stock	Market Cap	Close Price	Price Change	TTM Total Return	5Y CAGR	10Y CAGR	Compare
1RCKT	$270.25M	$2.48	-5.17%	-17.07%	-38.33%	-23.48%	N/A
2VNDA	$270.01M	$4.49	-1.97%	-15.59%	-23.91%	-11.90%	vs RCKT
3TMCI	$269.87M	$4.16	-7.14%	-29.44%	-29.41%	N/A	vs RCKT
4SABS	$269.40M	$2.96	-4.49%	+50.19%	-50.16%	N/A	vs RCKT
5FATE	$272.17M	$2.33	-3.91%	+100.16%	-46.86%	-2.31%	vs RCKT
6TLSI	$267.85M	$4.35	-0.68%	-5.17%	-15.05%	N/A	vs RCKT

Period	Low	Avg	High	# Analysts
Quarter ending Sep 2026	$-0.44	$-0.40	$-0.31	4
Quarter ending Dec 2026	$-0.57	$-0.41	$-0.25	4
Quarter ending Mar 2027	$-0.38	$-0.38	$-0.38	1
Quarter ending Jun 2027	$-0.38	$-0.38	$-0.38	1

Period	Low	Avg	High	# Analysts
FY 2026	$-0.18	$-0.13	$-0.03	7
FY 2027	$-1.67	$-1.36	$-0.93	7

Period	Low	Avg	High	# Analysts
Quarter ending Sep 2026	$200000.00	$200000.00	$200000.00	6
Quarter ending Dec 2026	$687100.00	$687100.00	$687100.00	6
Quarter ending Mar 2027	$3.24M	$3.24M	$3.24M	3
Quarter ending Jun 2027	$3.66M	$3.66M	$3.66M	3

FY 2026	$476185.00	$1.11M	$1.67M	8
FY 2027	$3.14M	$11.27M	$18.50M	9

Rocket Pharmaceuticals, Inc.(RCKT) stock price and fundamentals

RCKT Price Chart

Business at a glance

RCKT Key Metrics

Total Return CAGR

RCKT Earnings Preview

Similar-Size Sector Stocks

RCKT Competitors' Key Metrics

RCKT Charts

Valuation Charts

Performance Charts

Dividend Charts

CAGR Charts

Financial Statement Charts

Other Charts

RCKT Analyst Ratings

RCKT Analyst Estimates

Earnings Per Share (EPS) Estimates

Revenue Estimates